Global Information
회사소개 | 문의

방광암 : 파이프라인 리뷰

Bladder Cancer - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 232863
페이지 정보 영문 999 Pages
가격
US $ 2,500 ₩ 2,858,500 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,717,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,575,500 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


방광암 : 파이프라인 리뷰 Bladder Cancer - Pipeline Review, H1 2018
발행일 : 2018년 05월 페이지 정보 : 영문 999 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

방광암 치료제의 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 대한 정보를 정리하여 전해드립니다.

서론

방광암의 개요

치료제 개발

방광암 : 기업에서 개발중인 치료제

방광암 : 대학/기관에서 연구중인 치료제

방광암 : 파이프라인 제품의 개요

방광암 : 기업에서 개발중인 제품

방광암 : 대학/기관에서 연구중인 제품

방광암 치료제 개발에 참여하고 있는 기업

방광암 : 치료제 평가

약제 개요

방광암 : 최근 파이프라인 동향

방광암 : 휴지중인 프로젝트

방광암 : 개발이 중지된 제품

방광암 : 제품 개발 마일스톤

부록

KSA 16.06.09

List of Tables

  • Number of Products under Development for Bladder Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Bladder Cancer - Pipeline by 4SC AG, H1 2018
  • Bladder Cancer - Pipeline by Abivax SA, H1 2018
  • Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
  • Bladder Cancer - Pipeline by Alligator Bioscience AB, H1 2018
  • Bladder Cancer - Pipeline by Altor BioScience Corp, H1 2018
  • Bladder Cancer - Pipeline by Amgen Inc, H1 2018
  • Bladder Cancer - Pipeline by AndroScience Corp, H1 2018
  • Bladder Cancer - Pipeline by ANP Technologies Inc, H1 2018
  • Bladder Cancer - Pipeline by APIM Therapeutics AS, H1 2018
  • Bladder Cancer - Pipeline by Archivel Farma SL, H1 2018
  • Bladder Cancer - Pipeline by Array BioPharma Inc, H1 2018
  • Bladder Cancer - Pipeline by Asana BioSciences LLC, H1 2018
  • Bladder Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2018
  • Bladder Cancer - Pipeline by Astellas Pharma Inc, H1 2018
  • Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018
  • Bladder Cancer - Pipeline by AstraZeneca Plc, H1 2018
  • Bladder Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
  • Bladder Cancer - Pipeline by Bavarian Nordic A/S, H1 2018
  • Bladder Cancer - Pipeline by Bayer AG, H1 2018
  • Bladder Cancer - Pipeline by BeiGene Ltd, H1 2018
  • Bladder Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
  • Bladder Cancer - Pipeline by Biocad, H1 2018
  • Bladder Cancer - Pipeline by BioCancell Ltd, H1 2018
  • Bladder Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
  • Bladder Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2018
  • Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Bladder Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Bladder Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2018
  • Bladder Cancer - Pipeline by Celgene Corp, H1 2018
  • Bladder Cancer - Pipeline by Celldex Therapeutics Inc, H1 2018
  • Bladder Cancer - Pipeline by Celprogen Inc, H1 2018
  • Bladder Cancer - Pipeline by Celsion Corp, H1 2018
  • Bladder Cancer - Pipeline by Celyad SA, H1 2018
  • Bladder Cancer - Pipeline by Cold Genesys Inc, H1 2018
  • Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2018
  • Bladder Cancer - Pipeline by CytomX Therapeutics Inc, H1 2018
  • Bladder Cancer - Pipeline by Cytori Therapeutics Inc, H1 2018
  • Bladder Cancer - Pipeline by Eddingpharm Inc, H1 2018
  • Bladder Cancer - Pipeline by Eisai Co Ltd, H1 2018
  • Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc, H1 2018
  • Bladder Cancer - Pipeline by Eli Lilly and Co, H1 2018
  • Bladder Cancer - Pipeline by Elsalys Biotech SAS, H1 2018
  • Bladder Cancer - Pipeline by EpiThany Inc, H1 2018
  • Bladder Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2018
  • Bladder Cancer - Pipeline by Exelixis Inc, H1 2018
  • Bladder Cancer - Pipeline by Exicure Inc, H1 2018
  • Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Bladder Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2018
  • Bladder Cancer - Pipeline by Gene Signal International SA, H1 2018
  • Bladder Cancer - Pipeline by Genentech Inc, H1 2018
  • Bladder Cancer - Pipeline by Genmab A/S, H1 2018
  • Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Bladder Cancer - Pipeline by H3 Biomedicine Inc, H1 2018
  • Bladder Cancer - Pipeline by Hamlet Pharma AB, H1 2018
  • Bladder Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
  • Bladder Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H1 2018
  • Bladder Cancer - Pipeline by HitGen LTD, H1 2018

List of Figures

  • Number of Products under Development for Bladder Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H1 2018, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 52, 55, 1, 67, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 7, 3, 1, 12 and 3 molecules, respectively.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Bladder Cancer - Overview
  • Bladder Cancer - Therapeutics Development
  • Bladder Cancer - Therapeutics Assessment
  • Bladder Cancer - Companies Involved in Therapeutics Development
  • Bladder Cancer - Drug Profiles
  • Bladder Cancer - Dormant Projects
  • Bladder Cancer - Discontinued Products
  • Bladder Cancer - Product Development Milestones
  • Appendix
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research